7:21 AM ET
8-K
Business Update
Aquestive Therapeutics Business Update
Aquestive Therapeutics announced that the FDA has accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film as complete and assigned a PDUFA goal date of March 16, 2027. The resubmission follows positive results from studies designed to address a prior Complete Response Letter, positioning Anaphylm to potentially become the first oral rescue medication for severe allergic reactions.